August 28, 1998 |
Isis Pharmaceuticals Inc. of Carlsbad has won approval to sell the first of a new kind of drug that treats disease by switching off genes. The drug, Vitravene, slows down a serious eye infection that can blind people with AIDS. The approval by the Food and Drug Administration cheered researchers who have spent three decades trying to prove that such treatments were possible.
September 17, 2002 |
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research. Terms weren't disclosed. Isis said it granted licenses for certain patents to Sequitur, which agreed to make payments to Isis and limit the types of chemistry, called antisense, it can use in research. Isis had claimed that Sequitur was using Isis technology without permission.
January 11, 2005 |
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment. Writing down the value of assets such as equipment and patents will cost the company as much as $40 million in the fourth quarter. Additional expenses related to the firings will be recorded in the first quarter, Carlsbad, Calif.-based Isis said, without giving a specific figure.
June 6, 2003
* Isis Pharmaceuticals Inc., a Carlsbad drug developer whose experimental cancer medication failed in a study, said partner Eli Lilly & Co. waived repayment of the $21-million loan used to build the manufacturing facility for the drug.
September 14, 2007 |
Johnson & Johnson will pay Isis Pharmaceuticals Inc. about $275 million to develop two drugs for diabetes, Isis said. Carlsbad-based Isis will initially receive $45 million, and may be paid $230 million or more for meeting milestones for the as-yet unnamed medicines.
September 8, 2007 |
Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. have formed a venture uniting Nobel Prize winners David Baltimore and Phillip Sharp to create drugs from a newly discovered class of genetic material. The venture, Regulus Therapeutics, will have exclusive licenses from Alnylam and Isis for technology focused on so-called microRNAs. The molecules regulate networks of genes that may be involved in diseases including cancer, viral infections and metabolic disorders, the companies said.